Aarey Drugs files SEBI Reg. 74(5) Certificate for Quarter/Half Year Ended Sep 2025
Aarey Drugs submitted a Regulation 74(5) certificate for Q2/H1 FY26, confirming dematerialization process compliance for the period ended September 30, 2025, as per SEBI regulations.
This is a mandatory regulatory compliance update that does not contain information likely to significantly influence investor decisions or the company's operational or financial standing.
The announcement is a routine compliance filing confirming adherence to SEBI regulations regarding dematerialisation, which typically has no direct positive or negative impact on the company's financial performance or outlook.
Aarey Drugs & Pharmaceuticals Limited has submitted a Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. * The certificate is for the quarter and half year ended 30th September, 2025. * It was received from M/s. MUFG Intime India Private Limited, the company's Registrar and Share Transfer Agent. * The certificate confirms that securities received for dematerialisation during the quarter ended 30th September 2025 were confirmed (accepted/rejected) to the depositories. * It also states that the securities comprised in the said certificates have been listed on the stock exchanges where the earlier issued securities are listed. * Furthermore, it confirms that security certificates received for dematerialisation were mutilated and cancelled after due verification by the depository participant, and the name of the depositories has been substituted in the register of members as the registered owner within the prescribed timelines.
What to do with a filing like this
Aarey Drugs & Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under sebi compliance filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aarey Drugs & Pharmaceuticals Limited. Read the original for the full detail.